3-amino-6-trifluoromethyl-1,2,3,4-tetrahydrocarbazole | 147008-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-amino-6-trifluoromethyl-1,2,3,4-tetrahydrocarbazole
• 英文别名: 6-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine
• CAS: 147008-97-7
• 化学式: C₁₃H₁₃F₃N₂
• 分子量: 254.255
• InChiKey: RPRUKHVTDCBCDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1993000086A1

  公开（公告）日：1993-01-07

  (EN) Use of a compound of general formula (I), wherein R1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, arylC1-6alkoxy, -CO2R4, -(CH2)nCN, -(CH2)nCONR5R6, -(CH2)nSO2NR5R6, C1-6alkanolyamino(CH2)n, or C1-6alkylsulphonylamino(CH2)n; R4 represents hydrogen, C1-6alkyl or arylC1-6alkyl; R5 and R6 each independently represent hydrogen or C1-6¿alkyl, or R5 and R6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R2 and R3 each independently represent hydrogen, C¿1-6alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT1-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.(FR) Utilisation d'un composé de la formule (I) dans laquelle R1 représente hydrogène, halogène, trifluorométhyle, nitro, hydroxy, C1-6alkyle, C1-6alcoxy, arylC1-6alcoxy, -CO2R4, -(CH2)nCN, -(CH2)nCONR5R6, -(CH2)nSO2NR5R6, C1-6alcanoylamino(CH2)n, ou C1-6alkylsulphonylamino(CH2)n; R4 représente hydrogène, C1-6alkyle ou arylC1-6alkyle; R5 et R6 représentent chacun indépendamment hydrogène ou C1-6alkyle, ou R5 et R6 forment avec l'atome d'azote auquel ils sont attachés une chaîne fermée, n représente 0, 1 ou 2; et R2 et R3 représentent chacun indépendamment hydrogène, C1-6alkyle ou benzyle ou forment avec l'atome d'azote auquel ils sont attachés une chaîne fermée pyrrolidino, pipéridino ou hexahydroazépino; ou d'un sel physiologiquement acceptable de ce composé, dans la fabrication d'un médicament destiné au traitement d'états tels que la migraine où un agoniste analogue au 5-HT1 est prescrit. Des composés de la formule (I), leurs procédés de préparation et des compositions pharmaceutiques les contenant sont également décrits.

  使用通式（I）的化合物，其中R1代表氢，卤素，三氟甲基，硝基，羟基，C1-6烷基，C1-6烷氧基，芳基C1-6烷氧基，-CO2R4，-(CH2)nCN，-(CH2)nCONR5R6，-(CH2)nSO2NR5R6，C1-6酰胺基(CH2)n或C1-6烷基磺酰胺基(CH2)n; R4代表氢，C1-6烷基或芳基C1-6烷基; R5和R6各自独立地表示氢或C1-6烷基，或者R5和R6与它们所连接的氮原子一起形成一个环; n表示0，1或2; R2和R3各自独立地表示氢，C1-6烷基或苄基，或者与它们所连接的氮原子一起形成吡咯烷，哌啶或六氢噁唑环; 或其生理上可接受的盐，在制造用于治疗需要5-HT1样受体激动剂的情况的药物中，例如偏头痛。还描述了通式（I）的新化合物、制备它们的方法以及含有它们的制药组合物。
• Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0603432A1

  公开（公告）日：1994-06-29

  Use of a compound of general formula (I): wherein : R¹represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, arylC₁₋₆alkoxy, -CO₂R⁴, -(CH₂)nCN, -(CH₂)nCONR⁵R6, -(CH₂)nSO₂NR⁵R6, C₁₋₆alkanoylamino(CH₂)n, or C₁₋₆alkylsulphonylamino (CH₂)n; R⁴represents hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; R⁵ and R⁶each independently represent hydrogen or C₁₋₆alkyl, or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a ring; nrepresents 0, 1 or 2; and R² and R³each independently represent hydrogen, C₁₋₆alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT₁-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  使用通式（I）的化合物，其中：R¹代表氢、卤素、三氟甲基、硝基、羟基、C₁₋₆烷基、C₁₋₆烷氧基、芳基C₁₋₆烷氧基、-CO₂R⁴、-(CH₂)nCN、-(CH₂)nCONR⁵R6、-(CH₂)nSO₂NR⁵R6、C₁₋₆烷酰胺基(CH₂)n或C₁₋₆烷基磺酰胺基(CH₂)n；R⁴代表氢、C₁₋₆烷基或芳基C₁₋₆烷基；R⁵和R⁶分别独立地代表氢或C₁₋₆烷基，或R⁵和R⁶与它们所连接的氮原子一起形成一个环；n代表0、1或2；而R²和R³分别独立地代表氢、C₁₋₆烷基或苯甲基，或与它们所连接的氮原子一起形成吡咯烷基、哌啶基或六氢杂环庚基；或其生理上可接受的盐，在制备治疗5-HT₁样受体激动剂适用的病症的药物方面使用，例如偏头痛。还描述了通式（I）的新化合物、制备它们的方法以及含有它们的制药组合物。
• USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT 1? RECEPTOR AGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0591280A1

  公开（公告）日：1994-04-13